



## A STUDY ON EFFICACY OF AZITHROMYCIN IN UN-COMPLICATED ENTERIC FEVER IN EASTERN BIHAR.

**Dr. Kishore Kumar Sinha\*** Associate Professor, Department of Pediatrics, JLNMC, Bhagalpur, Bihar.  
\*Corresponding Author

**Dr. Anil Kumar** Junior Resident, Department of Pediatrics, JLNMC, Bhagalpur, Bihar.

**Dr. Brajesh Kumar** Senior Resident, Department of Pediatrics, JLNMC, Bhagalpur, Bihar.

**ABSTRACT** **INTRODUCTION:** Enteric fever, caused by *Salmonella typhi* and *Salmonella paratyphi*, is the leading cause of bacterial febrile disease in South Asia. Enteric fever is a systemic infection caused by the bacteria, *Salmonella Typhi* (*S. typhi*) and *Salmonella Paratyphi* (*S. paratyphi* A, B and C). Disease burden is more in the developing countries like India. There is day by day increase in the multidrug resistant strains.  
**OBJECTIVES:** The present study was conducted to assess the efficacy of azithromycin as a first line antibiotic in the treatment of uncomplicated enteric fever.  
**METHODS:** This case series study was conducted in Jawahar Lal Nehru Medical College And Hospital, Bhagalpur, Bihar in which 180 children between 2- 12 years of age were enrolled for the study. Those patients who were Typhidot and/or blood culture positive were included in this study and treated with azithromycin 20mg/kg/ single dose daily for 7 days.  
**RESULTS:** In the present study, out of the 180 children enrolled, 162 (90.00%) completed the study and eighteen children lost to follow up. Male to female ratio was 1.5:1 and the common age group in which typhoid fever was seen, was found to be 6-10 years. *S. typhi* was isolated in 10 (6.17%) cases and all achieved bacteriological cure by day 7. Mean (SD) duration of fever at presentation was 6±2.07 days. Clinical cure was seen in 152 (93.82%) subjects. Mean day of response was 4 days. There was no death or serious adverse effects observed in our study.  
**CONCLUSION:** In our study it was found that Azithromycin was safe and efficacious for the management of uncomplicated typhoid fever in a dose of 20 mg/kg/day per oral once a day for seven days. Oral azithromycin could be a convenient and cheap alternative for the treatment of typhoid fever, especially in children in developing countries like India where medical resources are scarce.

**KEYWORDS :** Enteric Fever, *Salmonella typhi*, Azithromycin.

### INTRODUCTION:

The typhoid fever caused by *Salmonella typhi* remains a serious problem in developing countries like India. It is estimated that more than 26.9 million typhoid fever cases occur annually out of which 1% result in death[1]. The vast majority of this infectious disease is mainly witnessed in Asia. These figures are representing the clinical syndrome rather than the culture-proven typhoid fever cases. The typhoid infection is predominantly seen in school age children and young adults. However, this infection is reported to be milder in infants and very young children. There is a wide range of presentation with involvement of various organs. Besides, there is also a paucity of microbiology facilities in developing countries. For decades, chloramphenicol has been highly effective against *S. typhi* and *S. paratyphi*, and it often remains the antibiotic of choice for the treatment of typhoid fever [2, 3].

Typhoid Fever is a highly prevalent infection in the Indian subcontinent. Due to multidrug resistant strains in these areas, third generation cephalosporins, such as ceftriaxone, are the treatment of choice. However, the latter regimen exhibits a slow response with mean time of 5 to 7 days or even longer to defervescence, which could be attributed to poor penetration capability of the drug into cells, and thus difficulty to eradicate the bacteria from the intracellular niche. Typhoid fever is a systemic infection caused by the bacterium *Salmonella enteric* serotype typhi, a member of the family Enterobacteriaceae. This organism is an important cause of febrile illness in crowded and impoverished populations with inadequate sanitation that are exposed to unsafe water and food [4,5]. *Salmonella* is human restricted pathogen and it is faecal-oral in transmission.

*S. typhi* has no non-human vectors. An inoculum as small as 1, 00,000 organisms causes infection in more than 50% of healthy volunteers[6]. Because of the ready availability of the over-the-counter antibiotics and subsequent resistance to these drugs in areas of endemicity, enteric fever is harder to treat. Previously chloramphenicol was used to treat this infection but in 1980 emergence of resistance limited its use. This was followed by emergence of multidrug resistant (MDR) strains (combined resistance to chloramphenicol, ampicillin and cotrimoxazole) initially reported from India, Middle East and then from all over the world. There is emergence of resistance to first line drugs like chloramphenicol, ampicillin, and also cephalosporins [7].

On the other hand, widespread use of fluoroquinolones led to the emergence of *Salmonella Enterica* serovar Typhi and Paratyphi strains with reduced susceptibility to fluoroquinolones[8]. Widespread emergence of multidrug resistant *S. typhi* has necessitated the search for other therapeutic options for typhoid fever[9,10].

Azolides are another class of antibiotics which have shown promise in the treatment of typhoid fever. Azithromycin is the first drug of this class and studies comparing the efficacy of azithromycin with cefixime in adults and children with typhoid fever have reported it to be safe and efficacious[11,12].

Azithromycin has excellent penetration into most tissues and achievement in macrophages and neutrophils that are >100 fold higher than concentrations in serum. These together with azithromycin's long half-life of 72 hours, show potential in the therapeutic management of enteric intracellular pathogens[13]. Few studies are exclusively reported in children[14].

This case series study was done by us to assess the safety and efficacy of single daily dose of azithromycin for uncomplicated typhoid fever in children in Eastern Bihar.

### MATERIAL AND METHODS:

This is a case series study conducted in the department of Pediatrics, Jawahar Lal Nehru Medical College and Hospital, from May 2017 to April 2018. All the children between 2-12 years of age who had typhidot IgM and/or blood culture positive and diagnosed as uncomplicated enteric fever were included in the study. All those children who fulfilled the following criteria were excluded from the present study:

- Who had life threatening complication of enteric fever (seizures, shock or perforation).
- Who had congenital or acquired immunodeficiency.
- Who was already taking other antibiotics for more than 48 hours.
- Who had poor oral intake due to debility of the disease.

Consent was obtained from parents/guardians of all children. On day of admission a complete medical, treatment and vaccination history was recorded. Complete physical examination was carried out. All the

children between 2-12 years of age who presented with the signs and symptoms of enteric fever and not taking antibiotics for more than 48 hours before presentation were started Azithromycin (20 mg/kg/day) dispersible tablet/suspension for seven days in a single daily dose after sending CBC, blood culture and sensitivity and typhidot IgM. After getting the reports of blood culture and sensitivity and typhidot IgM, only those patients having blood culture or/and typhidot IgM positive were included in the present study.

In our study medication was dispensed and monitoring instruction were provided to each patient. Children were treated at their home and reassessed in the out-patient department on day 4, day 7 and day 30 after the start of the treatment. On day 4 and day 7 temperature charts and symptom diary was evaluated with a complete physical examination. Drug compliance was assessed by history and collecting the empty wrappers/bottles.

Children who were blood culture positive were evaluated on day 7 also for repeat blood culture. If the temperature increased or the clinical condition of the patient worsened or there was a serious drug reaction, patient was taken off from the study and treated with intravenous Ceftriaxone (75 mg/kg/day). All the follow ups were carried out in the out-patient department of the hospital, JLNMCB, Bhagalpur.

#### TYPES OF OUTCOME MEASURES:

**Clinical Response:** Resolution of symptoms and fever clearance (axillary temperature less than 38°C for >72 hours) was considered sustained after 7 days of treatment.

**Microbiological Response:** Was considered when the blood culture became negative for salmonella typhi or para typhi after 7 days of treatment.

**Clinical Failure:** Lack of resolution of symptoms by day 7 or development of a major complication of typhoid fever (intestinal perforation, shock or seizures).

**Microbiological Failure:** Blood culture positive on day 7 for S.typhi or S. paratyphi.

**Relapse:** Recurrence of fever along with signs and symptoms of typhoid fever within 4 weeks of completion of therapy, along with isolation of the organism in blood culture.

#### RESULTS:

In the present study we enrolled 180 children aged 2-12 years who fulfilled the inclusion criteria. Mean age at the time of presentation was 6.4±2.04 years. 120/180 (66.66%) patients were male while 60/180 (33.33%) were female. 126/180 (70.00%) belonged to middle class family while 54/180 (30.00%) were from the lower low socioeconomic background. Only 54/180 (30.00%) children had received antibiotics before presentation. None of the patients had received prior typhoid vaccination. There was no mortality amongst the patients included in our study.

**Table 1: Clinical characteristics of study children at baseline and follow up**

Clinical findings	Visit 1 (Day 0)		Visit 2 (Day 4)		Visit 3 (Day 7)	
	No.	Percentage	No.	Percentage	No.	Percentage
Fever	162	100.00	22	13.58	10	06.17
Headache	48	29.62	08	04.93	00	00
Constipation	12	07.40	04	02.46	00	00
Diarrhoea	28	17.28	08	04.93	00	00
Anorexia	36	22.22	22	13.58	06	03.70
Pain Abdomen	62	38.27	12	07.40	02	01.23
Hepatomegaly	116	71.60	68	41.97	20	12.34
Splenomegaly	34	20.98	22	13.58	08	04.93
Coated Tongue	144	88.88	120	74.07	20	12.34

**Table 2 : Physical Examination**

Clinical Findings	No. Of Patients	Percentage
Coated Tongue	152	93.82
Hepatomegaly	108	66.66
Abdominal Tenderness	68	41.97
Splenomegaly	42	25.92
Rose Spots	12	07.40

18/180 (10.00%) patients left the study. Out of these eighteen patients, 12 did not come at day 4 for visit and 6 did not come for visit on day 7. So the data from these 18 patients could not be collected completely. Only 162 patients completed the study. 54/162 (33.33%) patients had temperature between 101-102°F followed by 72/162 (44.44%) patients with 100-101°F while 36/162 (22.22%) had temperature between 103-104°F.

Fever clearance time (FCT) was 96 hours (4 days) in 140/162 (86.41%) patients. Fever settled at day 5 in 8/162 (4.93%) patients while on day 6 in 4/162 (2.46%) but in 10/162 (6.17%) patients fever took more than 7 days to settle. In 8/162 (4.93%) patients relapse was documented. Blood culture was positive in ten (6.17%) patients. All of these patients achieved bacteriological cure at 7th day. All the 162 patients had typhidot positive.

Treatment failure was observed in 10/162 (6.17%) children. These children were started on intravenous antibiotic (Ceftriaxone) and all improved by day 12-15.

#### DISCUSSION:

Enteric fever is one of the very common cause of febrile illness and is the major reason for seeking health service by the common people[15]. Due to the emergence of multidrug resistance to drugs (Chloramphenicol, Ampicillin, Cotrimoxa-zole), the need of newer drugs for the treatment of enteric fever is necessitated; the results with macrolides like Azithromycin is promising.

In the present study, a 7 day course of oral Azithromycin was found to be highly effective, showing efficacy of 93.82%. The efficacy of Azithromycin has also been established by other studies. Frenck et al 2004 showed a similar comparable high percentage of clinical response to azithromycin at an average rate which supports the present study[14].

The most common age group affected in our study was 6-10 years (45.33%), which is different from the study of Prajapati et al 2008 where result showed that common age group was 1-5 years[16].

The fever clearance time was 96 hours (4days) in 140 (86.41%) patients which is also comparable with the study done by Frenck et al 2004[14], where fever clearance time was 4.5 days.

The bacteriological cure was seen in all the ten patients in our study. Similar response was observed by the study done by Frenck et al 2004[14], where bacteriological cure with Azithromycin was also 100%. In our study study, Azithromycin was tolerated well. In only few patients, abdominal symptoms like diarrhoea and nausea was observed on 1st and 2nd day of treatment. But these symptoms did not require any therapy and settled by themselves although this cannot be proven; it is likely that many of the gastrointestinal tract symptoms were associated with the underlying disease and not with the treatment.

Males had higher incidence of the disease in our study (male to female ratio of 1.5:1). This is in accordance with the study done by Bhattarai et al 2003[17]. This study also showed that fever was present in all the patients followed by abdominal pain, headache and anorexia at the time of presentation which is similar to other studies[18,19].

The emergence of the resistant strains of S.typhi has become an area of concern for decades. Various trials have focused the mechanisms by which resistance to the first line drugs used in the therapeutic management of enteric fever develop. Hence the search for new drugs for which S.typhi shows evidence of clinical response.

Failure rate was found to be 10 out of 162 (6.17%) while the relapse rate was 8 out of 162 (4.93%). This has been observed in earlier studies on azithromycin[8]. The absence of relapse in the azithromycin group is similar to other studies[14,20,21].

This study was a case series; however other studies where comparison of Azithromycin was done with intravenous ceftriaxone, the results were comparable. So, we suggest more studies of Azithromycin in comparison with other drugs in our country so that the efficacy and safety of Azithromycin can be established and it can also reduce the economic burden on the developing countries like India with resource crunch by decreasing both morbidity and mortality.

**CONCLUSION:**

A macrolide like azithromycin can be given in a high dose of 20 mg/kg/day per oral once a day for 7 days (max 1000mg/day) in uncomplicated enteric fever and also it is the most affordable first-line option for these infections in areas of endemicity. As there is rise in the emergence of multidrug resistant strains, Azithromycin seems to be very effective in management of uncomplicated enteric fever. The injectable cephalosporin (ceftriaxone) and / or hospitalisation would prove to be a great economic drain and resource burden in a developing country like India.

**REFERENCES:**

1. Bhutta Zulfiqar Ahmed, Kliegman Stanton, St Geme, Schor Behrman. Enteric Fever(TyphoidFever). Nelson's textbook of pediatrics 2015;2:20<sup>th</sup> edition Chapter 1981388-92.
2. Acharya G, Butler T, Ho M, et al. Treatment of typhoid fever: randomized trial of a three-day course of ceftriaxone versus a fourteen-day course of chloramphenicol. *Am J Trop Med Hyg*, 1995, vol. 52 (pg. 162-5).
3. Islam A, Butler T, Kabir I, Alam NH. Treatment of typhoid fever with ceftriaxone for 5 days or chloramphenicol for 14 days: a randomized clinical trial. *Antimicrob Agents Chemother*, 1993, vol. 37(pg. 1572-5).
4. White taker JA, Franco-Pardes C, Dell RC, Del Rio C and Edupuganti S. Rethinking Typhoid vaccines: implications for travelers and people living in highly endemic areas. *J TravelMed*2009;16(1):46-52.
5. Crump JA, Mintz ED. Global trends in typhoid and paratyphoid Fever. *Clin Infect Dis* 2010; 50(2):241-46.
6. Levine MM, Tackett CO, Szein MB. Host- Salmonella infection: human trials. *Microbes Infect*2001;3(14-15):1271-79.
7. Gupta SK, Madalla F, Omondi MW, Whichard JM,Fields PI and Gerner-Smidt P,et al. Laboratory based surveillance of parathyroid fever in the United States: travel and antimicrobial resistance. *Clin Infect Dis*2008;46(11): 1656-63.
8. Parry CM, Thretfall EJ. Antimicrobial resistance in typhoidal and non-typhoidal salmonellae. *Curr Opin Infect Dis*2009;21(5):531-38.
9. Yanagi D, de Vries GC, Rahardjo D, Alimsardiono L, Warito EB and De I,et al. Emergence of fluoroquinolone resistant strains of Salmonella enterica in Surabaya, Indonesia. *Diagn Microbiol Infect Dis*.2009;64(4):422-26.
10. Aggarwal A, Ghosh A, Gomer S, Mitra M and Parikh AO. Efficacy and safety of azithromycin for uncomplicated typhoid fever: an open label non-comparative study. *Indian Pediatr*2011;48(11):553-6.
11. Capoor MR, Rawat D, Nair D,Hasan AS, Deb M and Aggarwal P. In vitro activity of azithromycin, newer quinolones and cephalosporins in ciprofloxacin- resistant Salmonella causing enteric fever. *JMedMicrobiol*2007;56(Pt11):1490-94.
12. Parry CM, Ho VA, Phuong le T, Bej PV, Lanh MN and Tung LT, et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin- azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. *Antimicrob Agents Chemother*. 2007; 51(3): 819-25.
13. Shah D. Role of Azithromycin in Enteric fever. *Indian J Pediatr* 2009; 46(1): 50-52.
14. Frenck RW Jr, Mansour A, Nakhla I, Sultan Y, Putnam S, Cappuccinelli P, et al. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. *Clin Infect Dis* 2004; 38(7): 951-57.
15. Joshi BG, Keyal K, Pandey R, et al. Clinical Profile and Sensitivity Pattern of Salmonella Serotypes in Children: A Hospital Based Study. *J Nepal Pediatr Soc* 2011; 31(3):180- 83.
16. Prajapati B, Rai GK, Rai SK, Uneti HC, Thapa M, Singh G, et al. Prevalence of Salmonella typhi and paratyphi infection in Children: a hospital based study. *Nepal Med Coll J* 2008; 10(4): 238-41.
17. Bhattarai PM, Bista KP, Dhakwa JR, et al. A clinical profile of enteric fever at Kanti Children Hospital. *J Nepal Pediatr Soc* 2003; 21: 50-53.
18. Ramaswamy G, Janakiraman L, Thiruvengadam V, et al. Profile of Typhoid fever in Children from Tertiary Care hospital in Chennai-South India. *Indian J Pediatr* 2010; 77(10): 1089-92.
19. Neopane A, Singh SB, Bhatta R, Dhital B, Karki DB. Changing spectrum of antibiotic sensitivity in enteric fever. *KUMJ* 2008; 6(1):12-15.
20. Girgis Butler NIT, Frenck RW, Sultan Y, Brown FM, Tribble D, et al., Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multi drug resistance. *Antimicrob Agents Chemother*. 1999;43:1441-44.
21. Chinh NT, Parry CM, Ly NT, Ha HD, Thong MX, Diep TS. et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multi drug resistant or nalidixic acid-resistant typhoid fever. *Antimicrobial Agents and Chemotherapy* 2000;44:1855-9.